.png){kind=icon}
.png){kind=icon}
Return
The proteasome: A suitable antineoplastic target
.png){kind=icon}
PRE
AI
J
DOI：10.1038/nrc1361.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
The proteasome is an abundant multi-enzyme complex that provides the main pathway for degradation of intracellular proteins in eukaryotic cells. As such, it controls the levels of proteins that are important for cell-cycle progression and apoptosis in normal and malignant cells; for example, cyclins, caspases, BCL2 and nuclear factor of kappaB. A proteasome inhibitor bortezomib - has been developed that has shown efficacy as an anticancer agent in the clinic. How can targeting such a universal, broadly active cellular component provide the selectivity and specificity that are required for cancer therapeutics?
Keywords:
NF-KAPPA-B
MULTICATALYTIC PROTEINASE COMPLEX
MOLECULAR-WEIGHT PROTEASES
CHYMOTRYPSIN-LIKE ACTIVITY
PS-341 INHIBITS GROWTH
MULTIPLE-MYELOMA CELLS
PHASE-I TRIAL
DRUG-RESISTANCE
INTRACELLULAR-LOCALIZATION
DOWN-REGULATION
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
66.8
Papers:
3.8K
Citations:
6.0W
Organization
No organization information available
Cited Papers